Close

First Patient Dosed in BioMarin (BMRN) BMN 111 Phase 2

January 14, 2014 8:03 AM EST Send to a Friend
BioMarin Pharmaceuticals, Inc. (Nasdaq: BMRN) has dosed the first child in the Phase 2 trial with BMN 111, an analog ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login